Diagnosis of Epstein-Barr virus infection in clinical serum samples by an SPR biosensor assay

0427702 - ÚMCH 2015 RIV GB eng J - Journal Article
Riedel, Tomáš - Rodriguez-Emmenegger, Cesar - de los Santos Pereira, Andres - Bědajánková, A. - Jinoch, P. - Boltovets, P. M. - Brynda, Eduard
Diagnosis of Epstein-Barr virus infection in clinical serum samples by an SPR biosensor assay.
Biosensors and Bioelectronics. Roč. 55, 15 May (2014), s. 278-284. ISSN 0956-5663. E-ISSN 1873-4235
R&D Projects: GA ČR GBP205/12/G118; GA MŠMT EE2.3.30.0029; GA MŠMT(CZ) ED1.1.00/02.0109
Institutional support: RVO:61389013
Keywords : surface plasmon resonance biosensor * real time diagnostics * Epstein–Barr virus infection
Subject RIV: CE - Biochemistry
Impact factor: 6.409, year: 2014

Label-free affinity biosensors offer a promising platform for the development of a new generation of medical diagnostic technologies. Nevertheless, when such sensors are used in complex biological media, adsorption of non-targeted medium components prevents the specific detection of the analyte. In this work, we introduce for the first time a biosensor assay based on surface plasmon resonance (SPR) capable of diagnosing different stages of Epstein–Barr virus (EBV) infections in clinical serum samples. This was achieved by simultaneous detection of the antibodies against three different antigens present in the virus. To prevent the interference of the fouling from serum during the measurement, the SPR chips were coated by an antifouling layer of a polymer brush of poly[oligo(ethylene glycol) methacrylate] grown by surface-initiated atom transfer radical polymerization. The bioreceptors were then attached via hybridization of complementary oligonucleotides. This allowed the sensor surface to be regenerated after measurement by disrupting the complementary pairs above the oligonucleotides' melting temperature and attaching new bioreceptors. In this way, the same sensing surface could be used repeatedly. The procedure used in this work will serve as a prototype strategy for the development of label-free affinity biosensors for diagnostics in blood serum or plasma samples. This is the first example of detection of marker of a disease in clinical serum samples by an optical affinity biosensor.
Permanent Link: http://hdl.handle.net/11104/0233333